利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.038 秒)

    Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
    3.
    发明公开
    Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells 有权
    确定肝细胞癌亚型和检测肝癌干细胞的方法

    公开(公告)号：EP2559773A1

    公开(公告)日：2013-02-20

    申请号：EP12179595.9

    申请日：2008-06-09

    申请人： The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services ,  The Ohio State University Research Foundation

    发明人： Wang, Xin Wei ,  Ji, Junfang ,  Yamashita, Taro ,  Croce, Carlo, M.

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/6893

    摘要： The invention relates to a method of determining a hepatocellular carcinoma (HCC) in a subject comprising: a) obtaining a sample from the subject, b) analysing the sample for the expression of one or more biomarkers of miR-181 family of biomarkers, c) correlating the expression of one or more of the miR-181 family of biomarkers with a subtype of HCC in the subject, and d) determining whether the over-expression and/or under-expression, as compared to expression levels in normal liver tissue and non-HCC tissue, is indicative of a HCC. The invention further provides, an inhibitor selected from a group consisting of at least one inhibitor of one or more of the miR-181 family of biomarker for use in, treating a subject with the HCC subtype. The inhibitor may comprise a reagent comprising a nucleic acid complementary to at least one biomarker selected from the group consisting of one or more of the miR-181 family of biomarkers, and combinations thereof. The invention also provides a composition comprising a therapeutically effective amount of a reagent comprising a nucleic acid complementary to at least one biomarker selected from a group consisting of one or more of the miR-181 family of biomarkers, and may comprise a beta-catenin inhibitor.

    摘要翻译： 本发明涉及测定受试者中肝细胞癌（HCC）的方法，其包括：a）从受试者获得样品，b）分析样品中miR-181家族生物标志物的一种或多种生物标志物的表达，c ）将受试者中一种或多种生物标志物的miR-181家族的表达与HCC亚型相关联，并且d）与正常肝组织中的表达水平相比，确定过表达和/或表达不足 和非HCC组织，表明HCC。 本发明还提供了一种抑制剂，其选自用于治疗患有HCC亚型的受试者的一种或多种miR-181家族生物标志物的至少一种抑制剂。 所述抑制剂可以包含含有与选自一种或多种miR-181家族生物标志物及其组合的至少一种生物标志物互补的核酸的试剂。 本发明还提供了一种组合物，其包含治疗有效量的试剂，所述试剂包含与选自一种或多种miR-181家族生物标志物的至少一种生物标志物互补的核酸，并且可以包含β-连环蛋白抑制剂 。

    MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
    9.
    发明公开
    MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors 审中-公开
    MicroRNA在胰腺内分泌和腺泡肿瘤中的表达异常

    公开(公告)号：EP2591794A1

    公开(公告)日：2013-05-15

    申请号：EP12185440.0

    申请日：2007-01-03

    申请人： The Ohio State University Research Foundation

    发明人： Croce, Carlo, M. ,  Calin, George

    IPC分类号： A61K38/00 ,  C12Q1/68

    CPC分类号： C12Q1/6886 ,  A61N1/30 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57438

    摘要： The present invention relates to a method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an increase in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer, wherein the type of pancreatic cancer is a pancreatic endocrine tumor (PET), and the at least one miR gene product is selected from the group consisting of: miR-103, miR-107, miR-125a, miR-99a, miR-99b, miR-125b-1, miR-342, miR-130a, miR-100, miR-132, miR-129-2, miR-125b-2 and a combination thereof. The invention also relates to a probe for hybridization comprising a miRNA selected from the above group.

    摘要翻译： 本发明涉及诊断受试者是否患有胰腺癌或处于发展胰腺癌的风险中的方法，包括测量来自所述受试者的测试样品中至少一种miR基因产物的水平，其中增加 测试样品中的miR基因产物相对于对照样品中相应的miR基因产物的水平表明受试者具有胰腺癌或处于发展成胰腺癌的风险中，其中胰腺癌的类型是 胰腺内分泌肿瘤（PET），并且所述至少一种miR基因产物选自：miR-103，miR-107，miR-125a，miR-99a，miR-99b，miR-125b-1，miR -342，miR-130a，miR-100，miR-132，miR-129-2，miR-125b-2及其组合。 本发明还涉及包含选自上述组的miRNA的杂交探针。